In spite of the fact that the Biolink Group is researching and developing drugs in areas with enormous potential (fields like cancer and cardiovascular drugs), we actually consider the potential of lowering chronic inflammation (CI) as having the largest medical potential and constituting the greatest commercial opportunity. It is today a known fact that CI is closely
related to oxidative stress and even to the Metabolic Syndrome.
Furthermore, CI appears to be related to the pathogenesis of about 90% of all chronic diseases!
It is a well-known fact that CI is closely related to the pathogenesis of chronic inflammatory
diseases such as cardiovascular diseases, diabetes, Alzheimer’s and many others. Recent
medical research has also proven CI to have a rather significant influence on the pathogenesis
Initial evidence of the molecular link between inflammation and cancer has been shown by researchers at the University of California, San Diego (UCSD) School of Medicine.
Featured as the cover article in the August 6, 2004 issue of the journal Cell, the study also demonstrated that inactivation of a gene involved in the inflammatory process (IKK-ß that normally triggers NF-KB) can dramatically reduce tumour development in mice with a gastrointestinal form of cancer.
A randomized, double blind, placebo-controlled study, involving more than 100 human beings concludes that Medox® lowers chronic inflammation (NF-KappaB), published in the American “The Journal of Nutrition” August 2007.
See also the study based on the Biolink Group anthocyanins, showing that Cyanidin lowers chronic inflammation (NF-KappaB), by influencing the cholesterol efflux, published in the American magazine “Arteriosclerosis, Thrombosis and Vascular Biology” March 14th 2007.
In the US in the year 2000, as an example, more than 80,000,000 people were treated for inflammatory diseases. About 500,000 of these people suffered from very severe side effects. 100,000 were hospitalized due to their use of drugs, and 20,000 of these people died due to medical side effects and complications (Ref: US Arthritis Foundation 2001). These are dramatic figures that are on the increase around the world.
The pharmaceutical industry is struggling (without too much success so far) to bring the market new inflammation fighting drugs, without heavy side effects.